Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2021

26.01.2021 | Original Article

Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis

verfasst von: Raseen Tariq, Maham Hayat, Darrell Pardi, Sahil Khanna

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostridioides difficile infection (CDI), with ~15% 1-year recurrence rate. Small studies have identified variable risk factors associated with FMT failure. We, therefore, performed a systematic review and meta-analysis to evaluate the predictors of FMT failure. A systematic search of Medline, Embase, and Web of Science was performed from January 2013 up to June 2020. Meta-analyses were performed using random-effects models and pooled adjusted odds ratios for risk factors reported in ≥2 studies were calculated. Overall, 2671 patients with recurrent CDI who underwent FMT in 12 studies were included. FMT failure occurred in 454 patients (16.9%) with median follow-up of 3 months (range 2–7.7 months). A total of 9 risk factors were identified in ≥2 studies. Meta-analysis showed that use of non- CDI antibiotics, presence of inflammatory bowel disease, poor quality of bowel preparation, CDI-related hospitalization before FMT, inpatient FMT, and severe CDI were associated with statistically significant increased risk of failure after FMT. Increasing age, female gender, and immunocompromised status were not associated with increased risk for FMT failure. Several risk factors (both modifiable and non-modifiable) are associated with FMT failure. Lower use of antibiotics in the post-FMT period and good bowel preparation at the time of FMT are associated with lower risk of failure after FMT. Additionally, patients with non-modifiable risk factors should be counseled to be particularly alert about recurrent symptoms after FMT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46(5):479–493. https://doi.org/10.1111/apt.14201CrossRefPubMed Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46(5):479–493. https://​doi.​org/​10.​1111/​apt.​14201CrossRefPubMed
3.
Zurück zum Zitat McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66(7):e1–e48. https://doi.org/10.1093/cid/cix1085CrossRefPubMedPubMedCentral McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66(7):e1–e48. https://​doi.​org/​10.​1093/​cid/​cix1085CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Tariq R, Pardi DS, Bartlett MG, Khanna S (2018) Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis:ciy721. https://doi.org/10.1093/cid/ciy721 Tariq R, Pardi DS, Bartlett MG, Khanna S (2018) Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis:ciy721. https://​doi.​org/​10.​1093/​cid/​ciy721
7.
Zurück zum Zitat Fischer M, Kao D, Mehta SR, Martin T, Dimitry J, Keshteli AH, Cook GK, Phelps E, Sipe BW, Xu H, Kelly CR (2016) Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 111:1024. https://doi.org/10.1038/ajg.2016.180CrossRefPubMed Fischer M, Kao D, Mehta SR, Martin T, Dimitry J, Keshteli AH, Cook GK, Phelps E, Sipe BW, Xu H, Kelly CR (2016) Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 111:1024. https://​doi.​org/​10.​1038/​ajg.​2016.​180CrossRefPubMed
9.
Zurück zum Zitat Ianiro G, Valerio L, Masucci L, Pecere S, Bibbò S, Quaranta G, Posteraro B, Currò D, Sanguinetti M, Gasbarrini A (2017) Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a three-year, single-centre cohort study. Clin Microbiol Infect Ianiro G, Valerio L, Masucci L, Pecere S, Bibbò S, Quaranta G, Posteraro B, Currò D, Sanguinetti M, Gasbarrini A (2017) Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a three-year, single-centre cohort study. Clin Microbiol Infect
10.
Zurück zum Zitat Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JR (2016) Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 22(10):2402–2409. https://doi.org/10.1097/MIB.0000000000000908CrossRefPubMed Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JR (2016) Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 22(10):2402–2409. https://​doi.​org/​10.​1097/​MIB.​0000000000000908​CrossRefPubMed
11.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012CrossRef Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012CrossRef
13.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRef DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRef
14.
Zurück zum Zitat Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337(8746):867–872CrossRef Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337(8746):867–872CrossRef
17.
Zurück zum Zitat Fischer M, Kelly CR, Phelps EL, Wang E, Roach B, Smith JD, Xu H, Kao DH (2017) Quality of bowel preparation does not affect outcome of fecal microbiota transplantation for the therapy Clostridium difficile infection. Gastroenterology 152(5):S1004–S1005 Fischer M, Kelly CR, Phelps EL, Wang E, Roach B, Smith JD, Xu H, Kao DH (2017) Quality of bowel preparation does not affect outcome of fecal microbiota transplantation for the therapy Clostridium difficile infection. Gastroenterology 152(5):S1004–S1005
19.
Zurück zum Zitat Ianiro G, Valerio L, Masucci L, Pecere S, Bibbo S, Quaranta G, Posteraro B, Curro D, Sanguinetti M, Gasbarrini A, Cammarota G (2017) Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 23(5):ARTN 337.e1. https://doi.org/10.1016/j.cmi.2016.12.025CrossRef Ianiro G, Valerio L, Masucci L, Pecere S, Bibbo S, Quaranta G, Posteraro B, Curro D, Sanguinetti M, Gasbarrini A, Cammarota G (2017) Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 23(5):ARTN 337.e1. https://​doi.​org/​10.​1016/​j.​cmi.​2016.​12.​025CrossRef
21.
Zurück zum Zitat Mendelson AH, Rifkin S, Shay J, Razvi MA, Lee LA (2017) Procedural-related and patient-related factors influence Clostridium difficile recurrence after fecal microbiota transplant. Gastroenterology 152(5):S949–S950CrossRef Mendelson AH, Rifkin S, Shay J, Razvi MA, Lee LA (2017) Procedural-related and patient-related factors influence Clostridium difficile recurrence after fecal microbiota transplant. Gastroenterology 152(5):S949–S950CrossRef
22.
Zurück zum Zitat Patron RL, Hartmann CA, Allen S, Griesbach CL, Kosiorek HE, DiBaise JK, Orenstein R (2017) Vancomycin taper and risk of failure of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Clin Infect Dis 65(7):1214–1217CrossRef Patron RL, Hartmann CA, Allen S, Griesbach CL, Kosiorek HE, DiBaise JK, Orenstein R (2017) Vancomycin taper and risk of failure of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Clin Infect Dis 65(7):1214–1217CrossRef
23.
Zurück zum Zitat Tiwari A, Sharma H, Qamar K, Alastal Y, Abdelfattah T, Ammari Z, Simo H, Khan M, Nawras A (2018) Sa1844-factors predicting relapse of Clostridium difficle colitis following fecal microbiota transplantation (FMT). Gastroenterology 154(6):S-416–S-417CrossRef Tiwari A, Sharma H, Qamar K, Alastal Y, Abdelfattah T, Ammari Z, Simo H, Khan M, Nawras A (2018) Sa1844-factors predicting relapse of Clostridium difficle colitis following fecal microbiota transplantation (FMT). Gastroenterology 154(6):S-416–S-417CrossRef
24.
Zurück zum Zitat Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH (2018) Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am J Transplant Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH (2018) Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am J Transplant
27.
Zurück zum Zitat Ohshima T, Osaki T, Yamamoto Y, Asai S, Miyachi H, Kamiya S (2018) Evaluation of risk factors for Clostridium difficile infection based on immunochromatography testing and toxigenic culture assay. J Clin Microbiol 56(12). https://doi.org/10.1128/JCM.00555-18 Ohshima T, Osaki T, Yamamoto Y, Asai S, Miyachi H, Kamiya S (2018) Evaluation of risk factors for Clostridium difficile infection based on immunochromatography testing and toxigenic culture assay. J Clin Microbiol 56(12). https://​doi.​org/​10.​1128/​JCM.​00555-18
30.
Zurück zum Zitat Hourigan SK, Chen LA, Grigoryan Z, Laroche G, Weidner M, Sears CL, Oliva-Hemker M (2015) Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther 42(6):741–752. https://doi.org/10.1111/apt.13326CrossRefPubMed Hourigan SK, Chen LA, Grigoryan Z, Laroche G, Weidner M, Sears CL, Oliva-Hemker M (2015) Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther 42(6):741–752. https://​doi.​org/​10.​1111/​apt.​13326CrossRefPubMed
Metadaten
Titel
Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis
verfasst von
Raseen Tariq
Maham Hayat
Darrell Pardi
Sahil Khanna
Publikationsdatum
26.01.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2021
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-021-04163-z

Weitere Artikel der Ausgabe 7/2021

European Journal of Clinical Microbiology & Infectious Diseases 7/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.